1. 2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer
2. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH
3. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
4. Medicare program: changes to the hospital outpatient prospective payment system and CY 2008 payment rates, the ambulatory surgical center payment system and CY 2008 payment rates, the hospital inpatient prospective payment system and FY 2008 payment rates; and payments for graduate medical education for affiliated teaching hospitals in certain emergency situations Medicare and Medicaid programs: hospital conditions of participation; necessary provider designations of critical access hospitals. Federal Register website. https://www.federalregister.gov/documents/2007/11/27/07-5507/medicare-program-changes-to-the-hospital-outpatient-prospective-payment-system-and-cy-2008-payment. Published November 27, 2007. Accessed July 1, 2024.
5. Racial disparities in access to health care infrastructure across US counties: a geographic information systems analysis;Guo;Front Public Health.,2023